Basiliximab

Drug Profile

Basiliximab

Alternative Names: CHI 621; Chimeric RFT5; chRFT5; SDZ CHI 621; Simulect

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Novartis
  • Developer Cerimon Pharmaceuticals; Novartis
  • Class Monoclonal antibodies
  • Mechanism of Action Immunosuppressants; Interleukin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Renal transplant rejection; Transplant rejection
  • Discontinued Ulcerative colitis; Uveitis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 22 Sep 2014 Launched prior to this date for Renal transplant rejection in Argentina, Mexico, Canada, Venezuela, Chile, Indonesia, China, Malaysia, Philippines, Singapore, Hong Kong, South Africa, Australia, New Zealand, Belgium, Denmark, Ireland, Finland, France, Germany, Greece, Hungary, Poland, Portugal, Sweden, Czech Republic, Norway, Turkey, Russia & Ukraine (IV)
  • 22 Sep 2014 Launched prior to this date for Transplant rejection in Brazil & Thailand (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top